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Objectives: To evaluate the magnitude of serious adverse events (SAEs) observed in postmarketing
reports of tocilizumab (TCZ) for rheumatoid arthritis (RA) in relation to SAEs observed in TCZ clinical
trials and external epidemiology data.
Methods: A total of 64,000 patient-years (PY) of TCZ exposure was needed to determine, with 90%
power, whether rates of SAEs of interest (eg, death, hepatic, gastrointestinal, and cardiovascular) were
Z50% higher (agreed with the Food and Drug Administration) than expected. Reporting rates were
calculated for spontaneously reported SAEs, open-label or unblinded postmarketing clinical trials
(phase 3b/4), and a Japanese postmarketing surveillance program in the global postmarketing safety
database. Event rates were calculated for the registrational placebo-controlled trials and long-term
extension data. External comparators for anti-tumor necrosis factor (aTNF)-treated RA patients were
derived from a US-based health care insurance claims database or published literature.
Results: The global postmarketing safety database provided 65,099 PY of TCZ exposure; the aTNF
external comparator population provided 53,360 PY. Spontaneous reporting rates per 100 PY (95%
conﬁdence interval) were 8.3 (8.1, 8.5) SAEs, 0.39 (0.34, 0.44) deaths, 0.06 (0.04, 0.08) serious hepatic
events, 0.15 (0.12, 0.18) serious gastrointestinal events, 0.09 (0.07, 0.12) serious myocardial infarctions,
0.15 (0.12, 0.18) serious strokes, and 0.07 (0.05, 0.09) cardiac deaths in the global postmarketing safety
database. These were of similar magnitude to corresponding rates from registrational clinical trials, the
aTNF external comparator population, and published literature.
Conclusions: SAE rates observed among postmarketing TCZ users were similar to those of various
comparison populations. Predetermined design of studies to compare postmarketing AEs using multiple
data sources is a useful strategy that can be applied to other medications.
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Anti-tumor necrosis factor (aTNF) agents are the most com-
monly used biologic therapies in patients with rheumatoid arthri-
tis (RA) who have experienced inadequate response (IR) to
disease-modifying antirheumatic drugs (DMARDs) (DMARD-IR)
[1]. However, therapies that target other mediators in the patho-
genesis of RA are needed for these patients because up to 40% may
not respond adequately to aTNF agents [2–5].
One such mediator is interleukin-6 (IL-6), a key cytokine involved
in RA pathogenesis, with roles in both local and systemic manifes-
tations of the disease [6–8]. Tocilizumab (TCZ) is a humanized,
monoclonal, anti-human IL-6 receptor (IL-6R) antibody that binds
to membrane-bound and soluble forms of IL-6R [9], thereby blocking
IL-6-mediated signaling and its proinﬂammatory effects [10].
Overall, 5 pivotal phase 3 randomized controlled trials in
patients with RA and their long-term extensions (LTEs) demon-
strated the efﬁcacy and safety of TCZ in combination therapy with
DMARDs [11–14] and as monotherapy [15]. In the clinical trial
program, TCZ use was associated with laboratory changes
(eg, elevated transaminase and lipid levels and decreased neutro-
phil and platelet levels) [16], though no temporal relationship has
been observed between laboratory changes and clinical events.
TCZ was initially approved by the United States Food and Drug
Administration (FDA) for patients who did not respond to aTNF.
Clinical trials do not typically enroll a sufﬁcient number of
patients for relatively infrequent safety events to be detected. In
addition, the populations evaluated are generally homogeneous
and may not necessarily represent the diverse nature of the
expected postmarketing treatment population. Therefore, greater
cumulative exposure in more heterogeneous patient groups is
needed for full understanding of the risks associated with any
given therapy. Postmarketing surveillance through spontaneous
reporting, registries, and postmarketing studies are important
resources for the long-term detection of safety events [17,18]. As
part of continuous, ongoing pharmacovigilance programs, phar-
maceutical companies collect safety information from spontane-
ous reporting and from postmarketing studies designed to better
reﬂect the real-world treatment setting.
The current analysis describes a safety assessment conducted to
measure the rates of serious adverse events (SAEs) of interest
[serious hepatic events, serious gastrointestinal (GI) perforations,
and serious cardiovascular (CV) events] in the postmarketing
setting, where exposure to TCZ was greater than that inTable 1
Patient populations
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aTNF, anti-tumor necrosis factor; LTE, long-term extension; PY, patient-years; RA, rheum
a Published reports from the literature were used for events that could not be accuregistrational clinical trials and their LTEs. These rates were placed
in context with background rates observed in a United States aTNF
external health care insurance claims database comparator pop-
ulation. This assessment of a large postmarketing safety database
was requested by the FDA before approval of the expansion of this
new ﬁrst-in-class product into earlier use in the RA patient
population (ie, DMARD-IR patients). The agency agreed that once
64,000 patient-years (PY) of exposure was reached, analysis of the
global safety data would provide appropriate sensitivity to quan-
tify the risk for less-frequent SAEs of interest in patients treated
with TCZ. The purpose of this report is to illustrate the method-
ology by which a substantial TCZ postmarketing data set was
developed to enable better understanding of the proﬁles of these
less-frequent events in patients treated with TCZ.Methods
Reporting rates of SAEs of interest—serious hepatic events,
serious GI perforations, and serious CV events [myocardial infarc-
tion (MI) and stroke]—were estimated in 3 distinct patient data
sets (Table 1). The FDA deﬁnition of “serious” was used for this
analysis [19]. Reported event rates for TCZ were estimated from
the global postmarketing safety database population. Event rates
were also calculated from the registrational clinical trials all-
exposure (including placebo-controlled and LTE phases) popula-
tion. Background event rates were estimated from the aTNF
external health care insurance claims database comparator pop-
ulation, a retrospective cohort of aTNF-treated patients with
RA from a United States health care insurance claims database
(US MarketScans). No formal statistical testing was conducted
across these data sets because of differences inherent in their
compositions. Sample size calculations were performed to allow
for stable and precise estimates of event rates.
Sample size calculations were performed to determine the
number of TCZ-exposed PY needed to indicate a Z50% increase
in risk (as agreed with the FDA) of SAEs of interest over
estimated background rates derived from the aTNF external
health care insurance claims database comparator population.
Assumptions for the sample size analysis based on a Poisson
distribution included an observed rate (TCZ-exposed rate) Z50%
higher than the background rate based on the health care
insurance claims database, 2-sided α ¼ 0.05, and 90% power.
These calculations speciﬁed that the amount of TCZ exposureports—all spontaneous reports from TCZ-treated patients with RA, including
issing or no reported indications cumulative to July 29, 2011
rts from the literature, including those with missing or no reported indications
erature search spanning the period from October 11, 2010 to October 10, 2011 was
identify spontaneous reporting of unlisted AEs; 282 publications were identiﬁed
arketing surveillance program
-week, open-label study and a 3-year ongoing extension (including case report
ontaneous reports)
linded postmarketing clinical trials (phase 3b/4)
linded trials or ongoing open-label trials
this database were placebo-controlled and LTE studies (these were included in the
clinical trials all-exposure population), ongoing RA trials in the TCZ clinical
program, and blinded postmarketing RA trials
eived Z1 dose of TCZ in the phase 3 clinical trial program to a cutoff date of April
m patients with RA treated with aTNF in a United States health care insurance
sea
atoid arthritis; TCZ, tocilizumab.
rately deﬁned in the health care insurance claims database.
Table 2
Required sample size for the lower bound 95% CI to exceed background rates in
aTNF external health care insurance claims database comparator population
(assuming the observed rate is 50% greater)a
Event of interest aTNF background rateb
(per 100 PY)
TCZ PY
Serious hepatic events 0.10 63,913
Gastrointestinal perforation 0.14 45,653
Cardiovascular event (myocardial
infarction and stroke)
1.74 2744
aTNF, anti-tumor necrosis factor; CI, conﬁdence interval; PY, patient-years; TCZ,
tocilizumab.
a Assumption included rate ratio of 1.5, α of 0.05, and power of 0.9.
b Background rate was based on a cohort of 19,000 aTNF-treated patients with
rheumatoid arthritis in the aTNF external health care insurance claims database
comparator population.
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of the conﬁdence interval (CI) of the TCZ rate was greater than
the background rate (if the observed TCZ rate was 50% higher
than the background rate) was approximately 64,000 PY. This
calculated minimum exposure was considered sufﬁcient to
ensure that overlapping CIs were not merely an effect of too
few events or of too small an exposed patient population, which
would have resulted in very wide CIs. Background rates and
number of PYs needed for the proposed analysis were calculated
for each SAE of interest (eg, serious hepatic events, GI perfo-
rations, and CV events) (Table 2).Global postmarketing safety database population
Reporting rates of the SAEs of interest in the postmarketing
setting were based on the experience of TCZ-treated patients
recorded in the global postmarketing safety database (Table 3).
This database covers a range of sources, including all spontane-
ously reported adverse event (AE) data arising from the use of TCZ
in patients with RA. Spontaneous reports include those received
from regulatory authorities, published literature, Internet, lay
media (eg, television and newspapers), licensing partners, and
other pharmaceutical companies. Postmarketing reports from the
Japanese postmarketing surveillance program were also captured
in the global postmarketing safety database. Data from ongoingTable 3
Global postmarketing safety database population sources and exposure rates
Data sources contributing to global postmarketing
safety database population
Exposure to TCZ
(contribution to database), n
Spontaneous reports n ¼ 62,713a
US and Canada 8947
Published reports from the literature for RA ROW 26,7
Japanese postmarketing surveillance program Japan 25,0
Open-label/unblinded postmarketing clinical
trials (phase 3b/4)
n ¼ 5734c
Postmarketing trials 434
Total 65,0
PY, patient-years; RA, rheumatoid arthritis; ROW, rest of world; TCZ, tocilizumab; US, U
a Until July 29, 2011.
b Simulated data from global sales.
c Until August 12, 2011.
d Actual data.(cumulative until July 29, 2011) and completed open-label/
unblinded clinical trials (phase 3b/4) contributed to the global
postmarketing safety database. However, data from the 5 pivotal
registrational phase 3 trials and subsequent LTEs were excluded
from the global postmarketing safety database to avoid duplication
of patient data and were evaluated separately.Estimation of tocilizumab exposure in the global postmarketing safety
database population
The extent of TCZ exposure for the spontaneous reports and for
the Japanese postmarketing surveillance program reports that
contributed to the global postmarketing safety database popula-
tion was estimated from global sales data and was used as the
denominator for estimating reported rates of SAEs of interest from
these sources. The number of spontaneous and/or postmarketing
reports of SAEs of interest was used as the numerator. Global sales
data included vials sold for use outside the clinical trial setting and
in postmarketing clinical trials (including Japanese postmarketing
reports) using commercial TCZ until July 29, 2011. Countries were
grouped into United States and Canada, Japan, and rest of world
(ROW) for TCZ exposure calculations. The estimation of exposure
was based on total sales of TCZ and a series of assumptions,
including average weight of patients (72.3 kg, United States,
Canada, and ROW; 53.2 kg, Japan), average frequency of dosing,
and average dose per year (5762 mg, ROW; 5118 mg, United States
and Canada; 5069 mg, Japan). Except for average dose, given the
differences in the approved TCZ starting dose between ROW and
North America (8 mg/kg versus 4 mg/kg), exposure calculations for
ROW and the United States and Canada were based on the same
assumptions. Japan was treated as a separate region because of
more comprehensive data collection regarding exposure to TCZ in
the Japanese postmarketing surveillance program. The total
amount of TCZ sold per country per year (milligrams) was divided
by the average annual dose per patient to give the PY of exposure.
Assumptions used were based on data from clinical trials and
market research conducted in Europe and the United States.
Assumptions used for Japan were based on data collected from
the Japanese postmarketing surveillance program (average dose,
average body weight, and average number of doses per year).
Assumptions used to estimate the average frequency of dosing in
ROW were derived from a longitudinal market research study¼ 68,447
Exposure to TCZ by length of exposure, months
(contribution to database)
PYb (13.7%) Z 24 n ¼ 8664 (13.8%)
12 PYb (41.0%) 18 to o24 n ¼ 5401 (8.6%)
95 PYb (38.5%) 12 to o18 n ¼ 12,466 (19.9%)
6 to o12 n ¼ 18,247 (29.1%)
o6 n ¼ 17,933 (28.6%)
5 PYd (6.7%) Z 24 n ¼ 255 (4.4%)
18 to o24 n ¼ 697 (12.2%)
12 to o18 n ¼ 648 (11.3%)
6 to o12 n ¼ 1014 (17.7%)
o6 n ¼ 3120 (54.4%)
99 PY (100%)
nited States.
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1710 dosing intervals between February 2009 and August 2010.
Calculation of TCZ exposure for patients in open-label/
unblinded postmarketing clinical trials (phase 3b/4) that contrib-
uted to the global postmarketing safety database population used
reported events as the numerator and extent of TCZ exposure in
postmarketing trials in RA patients (calculated using actual expo-
sure data from global and local open-label/unblinded phase 3b/4
clinical trials) as the denominator (Table 3).
Safety analysis in the global postmarketing safety database
population
The safety analysis estimated reporting rates of exposure for
deaths, overall SAEs, and 3 SAEs of interest for TCZ [serious hepatic
events, serious GI perforation, and serious CV events (MI and
stroke)]. Multiple occurrences of SAEs were counted multiple
times. Transient ischemic attacks were excluded from the calcu-
lation for stroke rates because they are generally assessed sepa-
rately from stroke in epidemiological studies of CV events in
patients with RA [20]. SAEs of interest were deﬁned using
published Standardised MedDRA Queries, MedDRA High Level
Terms, AE grouped terms developed by the sponsor, and/or
medical review. All SAE reporting rates were expressed per 100
PY and included 95% CIs for the overall medical concept.
Based on size estimations from the aTNF external health care
insurance claims database comparator population, analysis of the
global postmarketing safety database was performed once it was
calculated that at least 64,000 PY of TCZ exposure had been
reached.
Registrational clinical trials all-exposure population
Pooled event rates in the placebo-controlled and LTE periods of
TCZ registrational clinical trials were estimated using 4009
patients who received at least 1 dose of double-blind and/or
open-label TCZ in the phase 3 clinical program until a cutoff date
of April 1, 2011. Patients who were DMARD-IR naive (n ¼ 2904),
aTNF-IR naive (n ¼ 464), or methotrexate (MTX) naive (n ¼ 417)
were included.
Calculation of tocilizumab exposure in the registrational clinical trials
all-exposure population
Event rates in the registrational clinical trials all-exposure
population were calculated using events reported in the trials as
the numerator and total PY of TCZ exposure in the trials as the
denominator. Total TCZ exposure was calculated as the sum of
individual patient exposure from TCZ registrational clinical trials
(which did not contribute to the global postmarketing safety
database population). The extent of exposure (PY) until April 1,
2011, was calculated as the number of infusions actually received
(missed doses excluded) plus up to 28 days per infusion. Duration
of the study (PY) until April 1, 2011 was calculated as the date of
the last safety observation minus the date of the ﬁrst dose plus 1.
Safety analysis in the registrational clinical trials all-exposure
population
Event rates were estimated for deaths, SAEs, and SAEs of
interest. SAEs occurring more than 90 days after the last dose of
TCZ were reported only if they were considered by the investigator
to be related to treatment. Multiple occurrences of SAEs were
counted multiple times. The total PY used to calculate the rate of
death in the TCZ group was different from the PY used for other
SAEs because the time on escape therapy (escape to TCZ 8 mg/kgwas permitted per protocol in some studies for patients who did
not respond) was included for the group in which it occurred.
aTNF external health care insurance claims database comparator
population
To provide an expected background rate of events and to
compare reported rates in TCZ-treated RA patients with expected
rates in biologic-treated RA patients, event rates of the SAEs of
interest were calculated using data from the aTNF external health
care insurance claims database comparator population. These data
were based on claims from patients treated with aTNF biologics
licensed for the treatment of RA patients who were DMARD-IR.
Events that could not be accurately identiﬁed in health insurance
claims data (eg, “any” SAE or death) were compared with event
rates published in the literature. Background event rates of SAEs of
interest were calculated using events identiﬁed through Interna-
tional Classiﬁcation of Diseases, Ninth Revision, Clinical Modiﬁcation
(ICD-9-CM) diagnostic and National Drug Code for Healthcare
Common Procedure Coding System procedure codes as the numer-
ator and the total PY of exposure included in the aTNF external
health care insurance claims database comparator population as
the denominator. RA patients receiving aTNF agents were classiﬁed
as having SAEs of interest if the patient had a hospital claim with
overnight stay and an ICD-9-CM diagnosis code indicative of the
SAE of interest. Emergency room visits without overnight stay
were not counted as SAEs. Hospital stays involving diagnostic
codes associated with AEs of interest were used in previously
published epidemiological studies as proxies for categorizing AEs
as serious [21–23]. The index date for follow-up was deﬁned as the
ﬁrst aTNF prescription after RA diagnosis. Retrospectively collected
patient health care insurance claims records [for all patients in the
intent-to-treat population (those who discontinued treatment or
who switched to another biologic agent)] were followed up from
the index date until the ﬁrst occurrence of the AE of interest or
until disenrollment from the database.Results
Patient characteristics
An estimated 68,447 patients were included in the global
postmarketing safety database population—62,713 from global
sales data (including the Japanese postmarketing surveillance
program) and 5734 from the open-label or unblinded postmarket-
ing clinical trials (phase 3b/4) (Table 3). Most patients reporting an
event were from Japan (37.5%), Europe (32.2%), and North America
(15.2%). Demographic data and baseline disease characteristics of
patients contributing to the global postmarketing safety database
are not consistently reported. However, available data indicate that
median age was 59 years and that most reports were for female
patients (79.2%), consistent with data for the RA population in
general [24]. The total extent of exposure to TCZ in the global
postmarketing safety database population was an estimated
65,099 PY, most (80%) of which was based on sales data from
ROW and Japan. Based on analysis of the global sales data,
approximately 59% of patients were exposed to TCZ for an average
of r12 months, 28% were exposed for 12–24 months, and 13%
were exposed for Z24 months (Table 3).
In the registrational clinical trials all-exposure population, 4009
patients received at least 1 dose of TCZ. Demographic and baseline
disease characteristics among RA patients who were MTX-naive,
DMARD-IR, and aTNF-IR were comparable. Slight numerical differ-
ences in disease parameters reﬂect differences in duration and
severity of disease among these 3 subpopulations. Median age at
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and most (Z80%) patients were women. Patients had moderate to
severe active RA, as indicated by a median Disease Activity Score
using 28 joints ranging from 6.3 to 6.8. The extent of exposure to
TCZ in the registrational clinical trials all-exposure population was
13,503 PY (from the ﬁrst dose of TCZ); of the 4009 patients, 700
(17%) were exposed for r12 months, 884 (22%) were exposed for
13–48 months, and 2425 (61%) were exposed for Z4 years. The
DMARD-IR subpopulation contributed 11,126 PY of the total 14,994
PY duration of exposure. Median duration during the trial was
4.56 years.
In the aTNF external health care insurance claims database
comparator population, of the 95,154 patients with at least
one diagnosis code for RA who were 18 years of age or older,
69,246 (72.8%) were women; approximately 17% were younger
than 45 years of age, 52% were 45–64 years of age, and 31% were
older than 65 years of age. Average observation time for these
patients was approximately 2.8 years. The 19,000 patients who
were treated with one or more aTNF agents provided a maximum
of 53,360 PY of cumulative follow-up (PY of follow-up varied
slightly for different types of AEs because of censoring of event
occurrence) after the initiation of aTNF therapy.
Safety analyses
Reporting event rates in the global postmarketing safety data-
base population, event rates in the registrational clinical trials all-
exposure population, and event rates in the aTNF external health
care insurance claims database comparator population (or pub-
lished data, where applicable) are shown in Table 4 [25,26]. Safety
results for the global postmarketing database population are also
detailed in Table 4.
In the global postmarketing safety database population, 253
patients were reported to have died after TCZ administration.
Therefore, the reporting rate of death was estimated to be at leastTable 4
Rates of SAEs in the analysis populations
Reporting Rate (95% CI) per 100 PY
Reporting event rate in TCZ
global postmarketing safety
database populationa
Event rate in TCZ
clinical trials all-e
populationb
Deaths 0.39 (0.34–0.44) 0.57 (0.45–0.70)
SAEs 8.30 (8.08–8.52) 14.63 (14.03–15.26
Serious hepatic events 0.06 (0.04–0.08) 0.04 (0.01–0.09)
Serious gastrointestinal
perforations
Overall 0.15 (0.12–0.18)f 0.20 (0.13–0.29)f
With corticosteroids – –
Without corticosteroids – –
Serious myocardial infarction
events
0.09 (0.07–0.12) 0.25 (0.18–0.35)
Serious stroke events 0.15 (0.12–0.18)h 0.25 (0.17–0.34)
Cardiac deaths 0.07 (0.05–0.09) 0.13 (0.08–0.21)
aTNF, anti-tumor necrosis factor; CI, conﬁdence interval; MI, myocardial infarction;
tocilizumab.
a Simulated data from global sales.
b Actual data.
c Unadjusted mortality rate of aTNF-treated RA patients; based on meta-analysis dat
patients [26].
d Based on unadjusted event rate of aTNF-treated RA patients from 18 randomized
patients [26].
e aTNF external health care insurance claims database population.
f Medically conﬁrmed rate.
g Includes all codes for acute MI, including codes for asymptomatic MI diagnosed o
h Excluding transient ischemic attacks.
i Estimated mortality rate from cardiovascular disease causes from published data i0.39 (95% CI: 0.34, 0.44) deaths per 100 PY. Death rates calculated
using a published meta-analysis of data from 17 clinical trials of
aTNF-treated RA patients [26] were reported as 0.61 per 100 PY
(95% CI: 0.38, 0.91). For many patients, more than 1 AE was
recorded in the safety database as having led to death (401 events
were recorded for 253 deaths). Based on all recorded AEs leading
to death, the most common causes of death were infections and
infestations (89 patients with 114 AEs) and cardiac disorders (46
patients with 52 events).
The reported rate of overall SAEs in the global postmarketing
safety database population was estimated to be at least 8.30 (95%
CI: 8.08, 8.52) events per 100 PY; infections and infestations were
the most frequently reported SAEs [2.31 (95% CI: 2.20, 2.43) per
100 PY]. The overall SAE rate in the registrational clinical trials all-
exposure population and the rate estimated from a published
meta-analysis of 18 clinical trials in aTNF-treated RA patients [26]
were 14.63 (95% CI: 14.03, 15.26) and 16.46 (95% CI: 15.05, 17.97)
per 100 PY, respectively.
The reported rate of serious hepatic events in the global
postmarketing safety database population was estimated to be at
least 0.06 (95% CI: 0.04, 0.08) events per 100 PY, based on a total of
36 events reported in 31 patients. The event rate of serious hepatic
events in the registrational clinical trials all-exposure population
and in the aTNF external health care insurance claims database
population was 0.04 (95%: 0.01, 0.09) and 0.10 (95% CI: 0.08, 0.13)
per 100 PY, respectively (Table 4). The reported rate for serious GI
perforations in the registrational clinical trials all-exposure pop-
ulation was 0.34, (95% CI: 0.24, 0.47) per 100 PY using AE terms in
the Standard MedDRA Query (SMQ) for gastrointestinal perfora-
tion. However, this SMQ is relatively nonspeciﬁc (it includes
abscesses) and may potentially overestimate the true rate of
perforation. Therefore, a medical review of each case was per-
formed to determine whether it was a true perforation (see
Supplemental Material for criteria for medical conﬁrmation). The
rate of medically conﬁrmed events was 0.20 (95% CI: 0.13, 0.29).registrational
xposure
Event rate in aTNF external
health care insurance claims
database comparator
populationb
Event rate in aTNF published
literatureb
– 0.61 (0.38–0.91)c
) – 16.46 (15.05–17.97)d
0.10 (0.08–0.13)e –
0.14 (0.11–0.18)e –
0.15 (0.11–0.19) –
0.10 (0.03–0.24) –
0.64 (0.58–0.71)e,g –
0.69 (0.62–0.76)e –
0.24 (0.10–0.50)i
PY, patient-years; RA, rheumatoid arthritis; SAEs, serious adverse events; TCZ,
a of 17 trials with 23 combined deaths over 3800 combined PY of exposure in 4097
trials with 499 combined SAEs over a cumulative 3032 PY of follow-up in 3581
n electrocardiogram or other special investigation.
n a biologic (aTNF) registry in Spain [35].
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marketing safety database population was estimated to be at least
0.23 (95% CI: 0.19, 0.27) events per 100 PY, derived from 149
events in 120 patients based on the SMQ wide (i.e., broad terms);
the medically conﬁrmed rate was 0.15 (95% CI: 0.12, 0.18). In the
aTNF external health care insurance claims database population,
the reported rate was 0.14 (95% CI: 0.11, 0.18) per 100 PY (Table 4).
The reported rate of serious MI was estimated to be at least 0.09
(95% CI: 0.07, 0.12) events per 100 PY in the global postmarketing
safety database population; this rate is based on 60 events in 59
patients. Serious stroke events (ischemic and hemorrhagic events
were combined; transient ischemic attacks were excluded) were
reported at a rate estimated to be at least 0.15 (95% CI: 0.12, 0.18)
events per 100 PY, based on 96 events in 87 patients.
Reporting rates of serious MI and stroke in the registrational
clinical trials all-exposure population and in the aTNF external
health care insurance claims database population can be found in
Table 4. A total of 46 deaths were reported in association with
cardiac events; therefore, the corresponding reporting rate of
cardiac deaths was estimated to be at least 0.07 (95% CI: 0.05,
0.09) events per 100 PY. Given that more than 1 event resulting in
death could be reported per patient, it is possible that not all 46
deaths were of direct cardiac origin.Discussion
Characterization of less-frequent safety events from purely
clinical trial data is limited by the number of patients enrolled
and the enrollment criteria that may not be representative of the
expected real-world postmarketing treatment population. The
approach described here attempted to overcome such challenges
in generating a data set of sufﬁcient exposure to deﬁne the
expected risk for less-frequent events in patients with RA treated
with TCZ. A TCZ postmarketing population with 64,000 PY of
exposure was formed by evaluating data from a variety of post-
marketing data sources (spontaneous reports, published reports
from the RA literature, postmarketing trials in patients with RA,
and a Japanese postmarketing surveillance program). Patients with
RA who are DMARD-IR are usually prescribed aTNF biologics [1];
therefore, background rates of SAEs of interest for TCZ were
estimated in a large aTNF external health care insurance claims
database comparator population or in the published literature.
This gave an indication of the number of PY of exposure to TCZ that
would be needed to conﬁdently ascertain that the rates of SAEs of
interest were neither underreported nor overreported in the
postmarketing setting or from the registrational clinical trial data.
In the current analysis, estimates of event rates in TCZ-treated
patients were from a heterogeneous and substantial global postmar-
keting safety data set with approximately 65,000 PY of exposure,
thus reﬂecting the use of TCZ in real-life clinical practice. The
minimum exposure required to rule out a 50% increase in risk
compared with background rates based on the aTNF external
health care insurance claims database comparator population
was estimated to be at least 64,000 PY. This volume of data
produced tight CIs across all end points of interest. Additional
exposure would make those CIs smaller; however, this would be
unlikely to produce any additional clinical insight. The study
sponsor felt that detecting a 50% increase in risk associated with
TCZ for the key safety events was a reasonable approach, given
the tradeoff between providing the information using the data
available versus delaying the analysis while waiting for addi-
tional data to accrue. This proposal was made to the FDA in a pre-
supplemental biologics license application meeting and was
approved. In future studies designed to meet pharmacovigilance
needs, alternative approaches such as testing a non-inferiorityhypothesis for safety events compared with an alternative
exposure (eg, anti-TNF agents) might also be considered.
Estimates based on all events from the Japanese postmarketing
surveillance program and the postmarketing open-label phase of
unblinded studies were obtained directly from the data collected
on case report forms during postmarketing programs and were
thus considered reliable.
Event rates of SAEs of interest calculated in the large aTNF
external health care insurance claims database comparator pop-
ulation were based on more than 50,000 PY of exposure frommore
than 19,000 RA patients treated with aTNF agents in real-world
clinical practice, including a sample of the elderly (Z65 years of
age) RA population representative of the United States general
population. The aTNF external health care insurance claims
database population in the current analysis provided more than
50,000 PY of follow-up in aTNF agent-exposed patients, which
allowed for the detection of relatively infrequent events that
cannot be identiﬁed in smaller, existing observational RA registries
that enroll aTNF agent-treated patients.
Incidence rates of SAEs of interest in the aTNF external health
care insurance claims database used in the current analysis were in
line with the limited published data. Analysis of 2 health care
databases (PharMetrics and Protocare) reported serious hepatic
event rates of 0.05 per 100 PY for biologic and nonbiologic
DMARD-treated patients with RA [21]. In the health care insurance
claims database in the current analysis, which used a similar
deﬁnition of serious hepatic events, the incidence rate was 0.10
per 100 PY (95% CI: 0.08, 0.13). The overall incidence rates of GI
perforations in the health care insurance claims database [0.14 per
100 PY (95% CI: 0.11, 0.18)] were within published ranges of 0.19
and 0.10 per 100 PY in patients with RA treated with biologic
therapies with or without concomitant corticosteroids, respec-
tively [27]. In patients treated with corticosteroids, the incidence
rate of GI perforations in the current health care insurance claims
database analysis [0.15 (95% CI: 0.11, 0.19) per 100 PY] was within
the range of previously published rates (0.11–0.19 per 100 PY)
[22,28]. Reports from the British Rheumatology Society Biologics
Registry estimated rates of MI and stroke among aTNF-treated
patients to be 0.48 per 100 PY (95% CI: 0.37, 0.61) and 0.39 per
100 PY (95% CI: 0.29, 0.53), respectively [29,30]. Incidence rates of
MI and stroke in the health care insurance claims database in the
current analysis were 0.64 per 100 PY (95% CI: 0.58, 0.71) and 0.69
per 100 PY (95% CI: 0.62, 0.76), respectively. Certain advantages
and limitations are associated with estimating background rates
using health care insurance claims data. Such data sources have
been used increasingly in pharmacovigilance for active safety
monitoring of new therapies during the postmarketing period.
Advantages of using electronic health care utilization records
include rapid and cost-efﬁcient access to health and drug pre-
scription records, availability of diagnostic and drug prescription
information recorded using standard coding systems (eg, ICD-9-CM
and National Drug Code), and large, population-based samples of
real-world health care utilization data [31–33]. Although health
care claims data are valuable for efﬁcient and effective examina-
tion of health care outcomes, most health care claims databases
have inherent limitations because they are collected primarily for
the purpose of reimbursement for health services and not for
research. Such limitations include potential miscoding of medical
events or occasional inclusion of diagnostic codes related to rule
out diagnostic workups. Therefore, to increase the speciﬁcity in
outcome identiﬁcation, hospitalization was required for all out-
come events in the current analysis [21–23]. In addition, ICD-9-CM
diagnostic codes were used for these conditions from published
epidemiological studies, and some claims-based algorithms are
based on high-quality validation studies (eg, myocardial infarction
and stroke; see Appendices A and B in Supplementary Materials
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Coding System/National Drug codes used) though the outcomes
in these analyses were not validated.
Despite its strengths, the methodology used in the current
analysis of the global postmarketing safety database and registra-
tional clinical trials all-exposure population also has limitations.
First, the event rates were obtained from various sources with
different methods of event deﬁnition, identiﬁcation, and reporting.
For example, in the global postmarketing safety database, data
from the postmarketing setting is subject to underreporting
because of the voluntary nature of safety reporting [34], whereas
the Japanese postmarketing surveillance program and the post-
marketing clinical trials are more akin to a registry and are subject
to strict and structured reporting of events [35]. This may account
for the higher proportion of events reported from Japan (37.5%)
compared with those reported from the United States and Canada
(15.2%). Additionally, the United States and Canada together
contributed only 14% of the total TCZ exposure in the global
postmarketing safety database, whereas Japan and ROW contrib-
uted 39% and 41%, respectively; this might also have contributed to
the higher proportions of events observed in these regions
compared with the United States and Canada. Furthermore, a key
and well-known limitation in the analysis of spontaneous reports
is that assumptions were made to estimate patients and PY of
exposure from sales data. Certain additional assumptions were
used in exposure calculations. For example, the estimates of
average annual patient exposure were based on 3 regions: United
States and Canada, Japan, and ROW; however, the average body
weight for the United States, Canada, and ROW were estimated
from market research conducted in the top 5 European countries.
The same average dose was used regardless of region, but average
weight likely varied per region/country.
Because of variations in the different analysis populations,
inconsistencies between patient characteristics and demography
are inherently probable. Although the populations were similar
with regard to age, sex, and duration on treatment, regional
variations in disease and treatment characteristics and potential
differences in general health status and comorbidities among
patients in the health care insurance claims database and in the
global postmarketing safety database may confound comparisons
of the incidence of SAEs.
Postmarketing rates of SAEs were comparable in an analysis
between Japan and ROW, except for reported rates of gastric
cancer, lymphoma, hematophagic histiocytosis, Pneumocystis
jiroveci pneumonia, atypical mycobacterial infection, bacterial
pneumonia, intestinal lung disease, and organizing pneumonia
(data not shown). As is the nature of all spontaneously reported
data, there is no ability to adjust for potential confounders in the
TCZ global postmarketing safety database population.
Case numerator is deﬁned differently by the health care
insurance claims database, the global postmarketing safety data-
base, and the registrational clinical trials all-exposure population.
Therefore, diagnoses of events and conditions differ among the
sources and may differ among regions and countries, which may
indirectly impact event identiﬁcation and reporting. The demo-
graphics of the full global postmarketing safety database popula-
tion could not be characterized because of the nature of
spontaneously reported data; only the demographics of patients
reporting an event were known. This limits comparisons between
the global postmarketing safety database population and other
patient populations in the current study and in other published
studies. An additional challenge was that postmarketing data were
assessed cumulatively until a single point, which did not allow for
assessment of changes in rates over time. TCZ has been available to
prescribers for a relatively short time, so average exposure to TCZ
in our study was comparatively short; approximately 59% of thepatients reporting an event were exposed for an average of 12
months or less. Information on the effects of longer cumulative
exposure to tocilizumab is limited.
In summary, despite the signiﬁcant advantage of providing a large
data set for this disease area, analysis of long-term safety for DMARD-
IR patients with RA in the postmarketing setting continues to be
challenging. There are inherent difﬁculties in assessing the exposed
population given the spontaneous nature of safety event reporting,
with limited epidemiological data on background rates and rates in
the exposed population (particularly for the early postmarketing
period). Addressing such challenges has necessitated the use of
different cross-disciplinary (pharmacovigilance, biostatistical, and
epidemiological) techniques, different data sources for estimation of
the exposed population, and calculation of background rates of safety
events for comparison with postmarketing data.
Overall, analysis of background event rates from the aTNF external
health care insurance claims database comparator population and
the published literature suggested that the reporting rates of SAEs—
including death and hepatic, gastrointestinal, and CV events—esti-
mated in the TCZ global postmarketing safety database were not
higher than the background rates expected in aTNF-treated patients
with RA. Furthermore, the observed rates of events determined from
the TCZ global postmarketing safety database population were no
greater than rates in the registrational clinical trials all-exposure
population using placebo-controlled and LTE data.Conclusions
The analyses presented illustrate an example of an integrated
approach with which postmarketing pharmacovigilance data can
be analyzed to improve understanding of a treatment's safety
proﬁle in the context of less-frequent events. They form the most
comprehensive and rigorous evaluation of TCZ safety to date and
were conducted to identify whether there was a Z50% increase in
risk compared with background rates in patients treated with
aTNF. Limitations of postmarketing data, particularly spontaneous
reporting (for which underreporting and missing data are
expected and exposures are based on assumptions), prevent
accurate comparison with other, more reliable, data sets. Conclu-
sions that event rates in the real world are consistent with those
observed in clinical trials, therefore, should be drawn with these
factors in mind. Nevertheless, in this case, analysis of a global and
substantial postmarketing database was informative in that it did
not identify greater risk for SAEs of interest for TCZ [serious
hepatic events, serious GI perforations, and serious CV events
(MI and stroke)] in the real-world setting. Long-term pharmaco-
vigilance will continue to inform the safety proﬁle.Acknowledgments
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